Dose Escalation of IPI-493 in Hematologic Malignancies

A Phase 1 Open-Label, Dose Escalation Study Evaluating the Safety and Tolerability of IPI-493 in Patients Experiencing Advanced Hematologic Malignancies With Client Proteins of Hsp90

The purpose of this study is to evaluate the safety, determine the maximum tolerated dose (MTD) and schedule of IPI-493 in patients with hematologic malignancies.

Inclusion Criteria:

• >/=18 years old
• ECOG 0-1
• confirmed hematological malignancy
• refractory to available therapy or for which no therapy is available
• adequate hepatic, renal function

Exclusion Criteria:

• active CNS malignancy
• prolonged QT interval
• significant GI/liver disease
• other serious concurrent illness or medical condition